Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TE
Real-world claims studies evaluating UZEDY® (risperidone) also show improved adherence and persistence…
Innovations in Fat, Sugar, and Salt Reduction to be Explored in IFT Webinar and at IFT FIRST
CHICAGO--(BUSINESS WIRE)--The Institute of Food Technologists (IFT), a nonprofit scientific organization committed…
VIVUS Announces Enrollment of First Patient in Phase 2 Clinical Trial Assessing Ethanol-Free Carmustine as a Component of High-Dose Chemotherapy Prior to Transplant in Patients with Hodgkin or Non-Hodgkin Lymphoma
April 14, 2025 09:00 ET | Source: VIVUS LLC — Innovative ethanol-free…
kdc/one and Clarion Group Announce Major Production and Packaging Joint Venture in Fast-Emerging Indian Market
Industry Leaders to Leverage Complementary Expertise and Industry-Leading Capabilities, Develop New Manufacturing…
Ever Joint Benefits: How This Supplement Supports Flexibility and Weight Loss
TALLMADGE, Ohio, March 22, 2025 (GLOBE NEWSWIRE) -- Weight management remains a…
Primera for Women: Natural Ingredients for Bladder Control & Pelvic Wellness
NASHVILLE, Tenn., March 22, 2025 (GLOBE NEWSWIRE) -- In today's fast-paced world,…
IBM and L’Oral to Build First AI Model to Advance the Creation of Sustainable Cosmetics
PARIS and NEW YORK, Jan. 16, 2025 /PRNewswire/ -- IBM (NYSE: IBM)…
IBM and L’Oral to Build First AI Model to Advance the Creation of Sustainable Cosmetics
PARIS and NEW YORK, Jan. 16, 2025 /PRNewswire/ -- IBM (NYSE: IBM)…
IBM and L’Oral to Build First AI Model to Advance the Creation of Sustainable Cosmetics
PARIS and NEW YORK, Jan. 16, 2025 /PRNewswire/ -- IBM (NYSE: IBM)…
IBM and L’Oral to Build First AI Model to Advance the Creation of Sustainable Cosmetics
PARIS and NEW YORK, Jan. 16, 2025 /PRNewswire/ -- IBM (NYSE: IBM)…